EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Chinese Expert Consensus on the Use of Biologics in Patients with Chronic Rhinosinusitis (2022, Zhuhai)

Hai-Yu Hong, Teng-Yu Chen, Qin-Tai Yang, Yue-Qi Sun, Feng-Hong Chen, Hong-Fei Lou, Hong-Tian Wang, Rui-Li Yu, Yun-Fang An, Feng Liu, Tian-Sheng Wang, Mei-Ping Lu und 38 weitere

ORL · 2023 · 85 (3) · 128-140

DOI: 10.1159/000529918 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ORL, online erschienen am 05.04.2023. Verfasst von Hai-Yu Hong und 49 weiteren Autor:innen. Beteiligte Einrichtung: Allergy Center, Department of Otolaryngology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China. Hauptthemen laut MEDLINE: Asthma, Biological Products, Nasal Polyps, Rhinitis. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: Chronic rhinosinusitis (CRS) is a common inflammatory disease in otolaryngology, mainly manifested as nasal congestion, nasal discharge, facial pain/pressure, and smell disorder. CRS with nasal polyps (CRSwNP), an important phenotype of CRS, has a high recurrence rate even after receiving corticosteroids and/or functional endoscopic sinus surgery. In recent years, clinicians have focused on the application of biological agents in CRSwNP. However, it has not reached a consensus on the timing and selection of biologics for the treatment of CRS so far. Summary: We reviewed the previous studies of biologics in CRS and summarized the indications, contraindications, efficacy assessment, prognosis, and adverse effects of biologics. Also, we evaluated the treatment response and adverse reactions of dupilumab, omalizumab, and mepolizumab in the management of CRS and made recommendations. Key Messages: Dupilumab, omalizumab, and mepolizumab have been approved for the treatment of CRSwNP by the US Food and Drug Administration. Type 2 and eosinophilic inflammation, need for systemic steroids or contraindication to systemic steroids, significantly impaired quality of life, anosmia, and comorbid asthma are required for the use of biologics. Based on current evidence, dupilumab has the prominent advantage in improving quality of life and reducing the risk of comorbid asthma in CRSwNP among the approved monoclonal antibodies. Most patients tolerate biological agents well in general with few major or severe adverse effects. Biologics have provided more options for severe uncontrolled CRSwNP patients or patients who refuse to have surgery. In the future, more novel biologics will be assessed in high-quality clinical trials and applied clinically.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaBiological ProductsNasal PolypsRhinitisSinusitisHumansChronic DiseaseConsensusOmalizumabQuality of LifeSteroids

Stichwörter der Autor:innen

BiologicsDupilumabMepolizumabOmalizumabRhinosinusitis

Substanzen

Biological ProductsOmalizumabSteroids

Autor:innen und Institutionen

  • Allergy Center, Department of Otolaryngology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China.
  • Allergy Center, Department of Otolaryngology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China, chenty57@mail2.sysu.edu.cn.
  • Department of Otolaryngology, Head and Neck Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
  • Department of Allergy, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
  • Department of Otolaryngology, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, China.
  • Department of Otolaryngology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.

Zitieren

APA

Hong, H. Y., Chen, T. Y., Yang, Q. T., Sun, Y. Q., Chen, F. H., Lou, H. F., Wang, H. T., Yu, R. L., An, Y. F., Liu, F., Wang, T. S., Lu, M. P., Qiu, Q. H., Wang, X. D., Chen, J. J., Meng, C. D., Xie, Z. H., Meng, J., Zeng, M., …, & Li, H. B. (2023). Chinese Expert Consensus on the Use of Biologics in Patients with Chronic Rhinosinusitis (2022, Zhuhai). ORL, 85(3), 128-140. https://doi.org/10.1159/000529918

Vancouver

Hong HY, Chen TY, Yang QT, Sun YQ, Chen FH, Lou HF, et al. Chinese Expert Consensus on the Use of Biologics in Patients with Chronic Rhinosinusitis (2022, Zhuhai). ORL. 2023;85(3):128-140. doi:10.1159/000529918

BibTeX
@article{Hong2023,
  author = {Hong, Hai-Yu and Chen, Teng-Yu and Yang, Qin-Tai and Sun, Yue-Qi and Chen, Feng-Hong and Lou, Hong-Fei and Wang, Hong-Tian and Yu, Rui-Li and An, Yun-Fang and Liu, Feng and Wang, Tian-Sheng and Lu, Mei-Ping and Qiu, Qian-Hui and Wang, Xiang-Dong and Chen, Jian-Jun and Meng, Cui-da and Xie, Zhi-Hai and Meng, Juan and Zeng, Ming and Xu, Cheng-Li and Wang, Ying and Yang, Yu-Cheng and Zhang, Wei-Tian and Tang, Jun and Yang, Yan-Li and Xu, Rui and Yu, Guo-Dong and Shi, Zhao-Hui and Wei, Xin and Ye, Hui-Ping and Sun, Ya-Nan and Yu, Shao-Qing and Zhang, Tian-Hong and Yong, Jun and Hang, Wei and Xu, Yuan-Teng and Xu, Yu and Tan, Guo-Lin and Sun, Na and Yang, Gui and Li, You-Jin and Ye, Jing and Zuo, Ke-Jun and Zhang, Li-Qiang and Wang, Xue-Yan and Yang, An-Ni and Xu, Ying-Xiang and Liao, Wei and Fan, Yun-Ping and Li, Hua-Bin},
  title = {Chinese Expert Consensus on the Use of Biologics in Patients with Chronic Rhinosinusitis (2022, Zhuhai)},
  journal = {ORL},
  year = {2023},
  volume = {85},
  number = {3},
  pages = {128--140},
  doi = {10.1159/000529918}
}
Kostenlos starten →